EUCTR2015-000167-14-IT进行中（未招募）1 期
HEAT-ACTIVATED TARGET THERAPY RADIOTHERAPY + HYPERTHERMIA + LYSO THERMOSENSITIVE LIPOSOMAL DOXORUBICIN) OF LOCALREGIONAL RELAPSE IN BREAST CANCER PATIENTS - HEAT-ACTIVATED TARGET THERAPY (RADIOTHERAPY + HYPERTHERMIA + LYSO-THERMOSENSITIVE LIPOSOMAL DOXORUBI
CELSION CORPORATIO0 个研究点目标入组 70 人开始时间: 2021年5月27日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Histologically documented recurrent denocarcinoma of the breast with a recurrence on the chest wall or its overlying skin:
- •Ulcerative chest wall disease defined as non-healing wounds consistent with cancer,
- •Inflammatory breast carcinoma,
- •Breast carcinoma not resected for medical reasons.
- •2.Tumor thickness, must be clinically indicated for hyperthermia therapy, as measured by clinical exam or radiological imaging studies (CT or MRI). The target local tumor lesion(s) must be able to be covered within two hyperthermia fields of treatment.
- •3.LRR Disease progression despite other available standard treatment options based on what is clinically indicated according to the investigator's clinical and medical judgment, including: one or more radiation treatment(s) to the chest wall.
- •4.Patients with stable distant bone metastasis; concomitant treatment with Zoledronic acid and Denosumab is allowed.
- •5.Non-pregnant female at least 18 years of age. If subject is of childbearing age, must have a negative serum pregnancy test at baseline and must agree to practice an acceptable form of birth control while on the study.
- •6.Provide written informed consent and willing to comply with protocol requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 35
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 35
排除标准
- •1.No concomitant cytotoxic antineoplastic therapy is allowed. Prior chemotherapy should not be administered within 5 half-lives or 28 days whichever is shorter.
- •2.Prior confirmed allergic reaction (including moderate rash, dyspnea, wheezing, urticaria or other symptoms) attributed to the administration
- •of either anthracyclines or other liposomally encapsulated drugs that required discontinuation of prior therapy.
- •3.Patients who have previously received hyperthermia in conjunction with either radiation therapy or chemotherapy.
- •4.Previous treatment with anthracyclines exceeding the following dosages: free doxorubicin (i.e. non- liposomal) and/or liposomal doxorubicin > 300 mg/m2 or epirubicin free > 540 mg/m2.
- •5.Previous (required active treatment within 5 years) or concomitant malignancy except basal cell cancer, in situ carcinoma of the cervix, or contralateral breast cancer. Subjects with a prior contralateral breast malignancy can be included if they did not receive any chemotherapy.
- •6.Baseline laboratories (to establish eligibility):
- •ANC Granulocytes < 1,500/ microliter
- •Platelets < 75,000/ microliter
- •Hemoglobin < 9 gm/dL
- •Total Bilirubin > 2 mg/dL
- •ALT and AST > 2.5 X upper limit of normal
- •Creatinine > 1.5 X upper limit of normal
- •7.ECOG/Zubrod Performance Status > 2.
- •8.MUGA/Echocardiogram Left Ventricular Ejection Fraction < 50%.
- •9.History of:
- •Acute coronary syndrome
- •Cerebral vascular accident
- •Abnormal cardiac stress testing within last 6 months
- •Symptomatic coronary artery disease
- •Uncontrolled hypertension or cardiomyopathy
- •Cardiac valvular surgery or open heart surgery
- •Known structural heart disease
- •10.Conditions which may interfere with hyperthermia portion of the trial such as: functioning cardiac pacemaker; metal plates, rods or prosthesis
- •of the chest wall, breast reconstruction with implants, severe numbness and/or tingling of the chest wall or breast, skin grafts and/or flaps on
- •the breast/chest wall.
- •11. Serious active infection requiring long-term antibiotic treatment.
- •12. Has received any external radiation therapy within 60 days prior to study enrollment.
- •13. Patients with parenchymal and known brain metastases; if metastasis is operated or irradiated the patient can be included in the study
研究者
相似试验
招募中
Unknown
Radiotherapy with hyperthermia for patients with high-risk prostate cancer; a multicenter prospective observational studyProstate cancerJPRN-UMIN000050538Aichi Medical University200
招募中
2 期
Cyberknife auto-planning high-dose intensity SBRT trialnon-small cell lung cancerJPRN-jRCTs032230014Onishi Hiroshi80
进行中（未招募）
不适用
Hyperfraktioniert akzelerierte Strahlentherapie (HART) mit Mitomycin C / 5-Fluorouracil versus Cisplatin / 5-Fluorouracil bei lokal fortgeschrittenen Kopf-Hals-Tumoren - HARTlokal fortgeschrittene Kopf-Hals-TumorenEUCTR2008-001584-11-ATMedUni Innsbruck Klinik für Strahlentherapie
撤回
2 期
Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer PatientsBreast CancerNCT02850419Imunon
招募中
2 期
Induction chemotherapy followed by radiotherapy in locally advanced head and neck cancers.CTRI/2023/08/056851Department of Radiotherapy and Radiation Medicine,